Kefir exhibits anti‑proliferative and pro‑apoptotic effects on colon adenocarcinoma cells with no significant effects on cell migration and invasion

Khoury,Nathalie; El‑Hayek,Stephany; Tarras,Omayr; El‑Sabban,Marwan; El‑Sibai,Mirvat; Rizk,Sandra

doi:10.3892/ijo.2014.2635

Kefir exhibits anti‑proliferative and pro‑apoptotic effects on colon adenocarcinoma cells with no significant effects on cell migration and invasion

Authors:
- Nathalie Khoury
- Stephany El‑Hayek
- Omayr Tarras
- Marwan El‑Sabban
- Mirvat El‑Sibai
- Sandra Rizk
View Affiliations

Affiliations: Department of Natural Sciences, Lebanese American University, Beirut 1102 2801, Lebanon, Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
Published online on: September 3, 2014 https://doi.org/10.3892/ijo.2014.2635
Pages: 2117-2127

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Kefir, a fermented milk product, exhibits anti‑tumoral activity in vivo; yet its mechanism of action remains elusive. Recent studies have focused on the mechanism of action of kefir on cancer cells in vitro. The current study aims at examining the effect of kefir on cell survival, proliferation, and motility of colorectal cancer (CRC) cells. Kefir's anti‑cancer potential was tested on CRC cell lines, Caco‑2 and HT‑29, through cytotoxicity, proliferation, and apoptotic assays. The expression of certain genes involved in proliferation and apoptosis was measured using reverse transcriptase‑polymerase chain reaction (RT‑PCR) and western blotting. To assess the effect of kefir on cancer metastasis, wound‑healing and time‑lapse movies, in addition to collagen‑based invasion assay, were used. The results show that cell‑free fractions of kefir exhibit an anti‑proliferative effect on Caco‑2 and HT‑29 cells. Analysis of DNA content by flow cytometry revealed the ability of kefir to induce cell cycle arrest at the G1 phase. Kefir was also found to induce apoptosis, as seen by cell death ELISA. Results from RT‑PCR showed that kefir decreases the expression of transforming growth factor α (TGF‑α); and transforming growth factor‑β1 (TGF‑β1) in HT‑29 cells. Western blotting results revealed an upregulation in Bax:Bcl‑2 ratio, confirming the pro‑apoptotic effect of kefir, and an increase in p53 independent‑p21 expression upon kefir treatment. MMP expression was not altered by kefir treatment. Furthermore, results from time‑lapse motility movies, wound‑healing, and invasion assays showed no effect on the motility of colorectal as well as breast (MCF‑7 and MB‑MDA‑231) cancer cells upon kefir treatment. Our data suggest that kefir is able to inhibit the proliferation and induce apoptosis in HT‑29 and Caco‑2 CRC cells, yet it does not exhibit a significant effect on the motility and invasion of these cells in vitro.

View Figures

View References

1	Adriana P and Socaciu C: Probiotic activity of mixed cultures of kefir’s lactobacilli and non-lactose fermenting yeasts. Agric. 65:329–334. 2008.
2	Farnworth ER: Kefir - a complex probiotic. Food Sci Technol Bull. 2:1–17. 2005.
3	Angulo L, Lopez E and Lema C: Microflora present in kefir grains of the Galician region (north-west of Spain). J Dairy Res. 60:263–267. 1993. View Article : Google Scholar : PubMed/NCBI
4	Lopitz-Otsoa F, Rementeria A, Elguezabal N and Garaizar J: Kefir: a symbiotic yeasts-bacteria community with alleged healthy capabilities. Rev Iberoam Micol. 23:67–74. 2006.PubMed/NCBI
5	Simova E, Simov Z, Beshkova D, Frengova G, Dimitrov Z and Spasov Z: Amino acid profiles of lactic acid bacteria, isolated from kefir grains and kefir starter made from them. Int J Food Microbiol. 107:112–123. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liu JR, Wang SY, Lin YY and Lin CW: Antitumor activity of milk kefir and soy milk kefir in tumor-bearing mice. Nutr Cancer. 44:182–187. 2002.PubMed/NCBI
7	Vinderola G, Perdigón G, Duarte J, Farnworth E and Matar C: Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranofaciens on the gut mucosal immunity. Cytokine. 36:254–260. 2006. View Article : Google Scholar : PubMed/NCBI
8	Hertzler SR and Clancy SM: Kefir improves lactose digestion and tolerance in adults with lactose maldigestion. J Am Diet Assoc. 103:582–587. 2003. View Article : Google Scholar : PubMed/NCBI
9	Liu JR, Wang SY, Chen MJ, Chen HL, Yueh PY and Lin CW: Hypocholesterolaemic effects of milk-kefir and soyamilk-kefir in cholesterol-fed hamsters. Br J Nutr. 95:939–946. 2006. View Article : Google Scholar
10	Preidis GA, Hill C, Guerrant RL, Ramakrishna BS, Tannock GW and Versalovic J: Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology. 140:8–14. 2011. View Article : Google Scholar : PubMed/NCBI
11	Chen C, Chan HM and Kubow S: Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells. J Med Food. 10:416–422. 2007. View Article : Google Scholar : PubMed/NCBI
12	Rodrigues KL, Caputo LR, Carvalho JC, Evangelista J and Schneedorf JM: Antimicrobial and healing activity of kefir and kefiran extract. Int J Antimicrob Agents. 25:404–408. 2005. View Article : Google Scholar : PubMed/NCBI
13	Shiomi M, Sasaki K, Murofushi M and Aibara K: Antitumor activity in mice of orally administered polysaccharide from Kefir grain. Jpn J Med Sci Biol. 35:75–80. 1982. View Article : Google Scholar : PubMed/NCBI
14	Murofushi M, Shiomi M and Aibara K: Effect of orally administered polysaccharide from kefir grain on delayed-type hypersensitivity and tumor growth in mice. Jpn J Med Sci Biol. 36:49–53. 1983. View Article : Google Scholar : PubMed/NCBI
15	Murofushi M, Mizuguchi J, Aibara K and Matuhasi T: Immunopotentiative effect of a polysaccharide from kefir grain, KGF-C, administered orally in mice. Immunopharmacology. 12:29–35. 1986. View Article : Google Scholar : PubMed/NCBI
16	Furukawa N, Matsuoka A and Yamanaka Y: Effects of orally administered yoghurt and kefir on tumor growth in mice. J Jpn Soc Nutr Food Sci. 43:450–453. 1990. View Article : Google Scholar
17	Kubo M, Odani T, Nakamura S, Tokumaru S and Matsuda H: Pharmacological study on kefir - a fermented milk product in Caucasus. I. On antitumor activity (1). Yakugaku Zasshi. 112:489–495. 1992.(In Japanese).
18	Rizk S, Maalouf K and Baydoun E: The antiproliferative effect of kefir cell-free fraction on HuT-102 malignant T lymphocytes. Clin Lymphoma Myeloma. (Suppl 3): S198–S203. 2009. View Article : Google Scholar : PubMed/NCBI
19	Maalouf K, Baydoun E and Rizk S: Kefir induces cell-cycle arrest and apoptosis in HTLV-1-negative malignant T-lymphocytes. Cancer Manag Res. 3:39–47. 2011.PubMed/NCBI
20	Furukawa N, Matsuoka A, Takahashi T and Yamanaka Y: Anti-metastatic effect of kefir grain components on Lewis lung carcinoma and highly metastatic B16 melanoma in mice. J Agric Sci Tokyo Nogyo Daigaku. 45:62–70. 2000.
21	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. Cancer J Clin. 2013.63:11–30
22	Hamilton SR: The molecular genetics of colorectal neoplasia. Gastroenterology. 105:3–7. 1993.PubMed/NCBI
23	Hoff G, Foerster A, Vatn MH, Sauar J and Larsen S: Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol. 21:853–862. 1986.PubMed/NCBI
24	Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Gastroenterology. 134:1296–1310. 2008. View Article : Google Scholar : PubMed/NCBI
25	Messersmith WA and Hidalgo M: Panitumumab, a monoclonal anti-epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res. 13:4664–4666. 2007. View Article : Google Scholar
26	Arteaga C: Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. (3 Supp 7): S3–S14. 2003. View Article : Google Scholar : PubMed/NCBI
27	Rodriguez-Bigas MA, Lin EH and Crane CH: Stage IV colorectal cancer. Holland-Frei Cancer Medicine. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF and Frei E: 2. 6th edition. Hamilton, ON: 2003
28	Hassan MS, Ansari J, Spooner D and Hussain SA: Chemotherapy for breast cancer (Review). Oncol Rep. 24:1121–1131. 2010. View Article : Google Scholar : PubMed/NCBI
29	Palmer TD, Ashby WJ, Lewis JD and Zijlstra A: Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev. 63:568–581. 2011. View Article : Google Scholar : PubMed/NCBI
30	Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, et al: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA. 103:7817–7822. 2006. View Article : Google Scholar : PubMed/NCBI
31	Liu C, Woo A and Tsao MS: Expression of transforming growth factor-alpha in primary human colon and lung carcinomas. Br J Cancer. 62:425–429. 1990. View Article : Google Scholar : PubMed/NCBI
32	Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ, Fidler IJ and Langley RR: Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol. 173:205–216. 2008. View Article : Google Scholar
33	Ueda M, Fujii H, Yoshizawa K, Terai Y, Kumagai K, Ueki K and Ueki M: Effects of EGF and TGF-alpha on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells. Invasion Metastasis. 18:176–183. 1998. View Article : Google Scholar : PubMed/NCBI
34	Hölting T, Siperstein AE, Clark OH and Duh QY: Epidermal growth factor (EGF)-and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol. 132:229–235. 1995.
35	Massagué J: TGFβ signalling in context. Nat Rev Mol Cell Biol. 13:616–630. 2012.
36	Halder SK, Beauchamp RD and Datta PK: A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 7:509–521. 2005. View Article : Google Scholar : PubMed/NCBI
37	Xiong B, Yuan HY, Hu MB, Zhang F, Wei ZZ, Gong LL and Yang GL: Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. World J Gastroenterol. 8:674–678. 2002.PubMed/NCBI
38	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
39	Ramesh S, Wildey GM and Howe PH: Transforming growth factor beta (TGFbeta)-induced apoptosis: the rise and fall of Bim. Cell Cycle. 8:11–17. 2009. View Article : Google Scholar : PubMed/NCBI
40	Akhurst RJ and Hata A: Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 11:790–811. 2012.
41	Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, Dezube BJ, Hsu FJ, Reiss M and Berzofsky JA: Phase I/II study of GC1008: a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol. 26(Suppl 15): S90282008.
42	Fidler IJ: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 3:453–458. 2003.